Glycogen stored in skeletal but not in cardiac muscle in acid α-glucosidase mutant (Pompe) mice is highly resistant to transgene-encoded human enzyme

Nina Raben, Tejas Jatkar, Alicia Lee, Nina Lu, Sunita Dwivedi, Kanneboyina Nagaraju, Paul H. Plotz

Research output: Contribution to journalArticle

Abstract

Although many lysosomal disorders are corrected by a small amount of the missing enzyme, it has been generally accepted that 20-30% of normal acid α-glucosidase (GAA) activity, provided by gene or enzyme replacement therapy, would be required to reverse the myopathy and cardiomyopathy in Pompe disease. We have addressed the issue of reversibility of the disease in the Gaa-/- mouse model. We have made transgenic lines expressing human GAA in skeletal and cardiac muscle of Gaa-/- mice, and we turned the transgene on at different stages of disease progression by using a tetracycline-controllable system. We have demonstrated that levels of 20-30% of normal activity are indeed sufficient to clear glycogen in the heart of young Gaa-/- mice, but not in older mice with a considerably higher glycogen load. However, in skeletal muscle - a major organ affected in infantile and in milder, late-onset variants in humans - induction of GAA expression in young Gaa-/- mice to levels greatly exceeding wildtype values did not result in full phenotypic correction, and some muscle fibers showed little or no glycogen clearance. The results demonstrate that complete reversal of pathology in skeletal muscle or long-affected heart muscle will require much more enzyme than previously expected or a different approach.

Original languageEnglish (US)
Pages (from-to)601-608
Number of pages8
JournalMolecular Therapy
Volume6
Issue number5
DOIs
StatePublished - Nov 1 2002
Externally publishedYes

Fingerprint

Glucosidases
Glycogen
Transgenes
Myocardium
Acids
Enzymes
Skeletal Muscle
Glycogen Storage Disease Type II
Enzyme Replacement Therapy
Muscular Diseases
Tetracycline
Cardiomyopathies
Disease Progression
Pathology
Muscles
Genes

Keywords

  • Acid α-glocosidase
  • Knockout
  • Myopathy
  • Pompe disease
  • Transgenic

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Glycogen stored in skeletal but not in cardiac muscle in acid α-glucosidase mutant (Pompe) mice is highly resistant to transgene-encoded human enzyme. / Raben, Nina; Jatkar, Tejas; Lee, Alicia; Lu, Nina; Dwivedi, Sunita; Nagaraju, Kanneboyina; Plotz, Paul H.

In: Molecular Therapy, Vol. 6, No. 5, 01.11.2002, p. 601-608.

Research output: Contribution to journalArticle

Raben, Nina ; Jatkar, Tejas ; Lee, Alicia ; Lu, Nina ; Dwivedi, Sunita ; Nagaraju, Kanneboyina ; Plotz, Paul H. / Glycogen stored in skeletal but not in cardiac muscle in acid α-glucosidase mutant (Pompe) mice is highly resistant to transgene-encoded human enzyme. In: Molecular Therapy. 2002 ; Vol. 6, No. 5. pp. 601-608.
@article{421406ee31f64cc491e5c6282676ab90,
title = "Glycogen stored in skeletal but not in cardiac muscle in acid α-glucosidase mutant (Pompe) mice is highly resistant to transgene-encoded human enzyme",
abstract = "Although many lysosomal disorders are corrected by a small amount of the missing enzyme, it has been generally accepted that 20-30{\%} of normal acid α-glucosidase (GAA) activity, provided by gene or enzyme replacement therapy, would be required to reverse the myopathy and cardiomyopathy in Pompe disease. We have addressed the issue of reversibility of the disease in the Gaa-/- mouse model. We have made transgenic lines expressing human GAA in skeletal and cardiac muscle of Gaa-/- mice, and we turned the transgene on at different stages of disease progression by using a tetracycline-controllable system. We have demonstrated that levels of 20-30{\%} of normal activity are indeed sufficient to clear glycogen in the heart of young Gaa-/- mice, but not in older mice with a considerably higher glycogen load. However, in skeletal muscle - a major organ affected in infantile and in milder, late-onset variants in humans - induction of GAA expression in young Gaa-/- mice to levels greatly exceeding wildtype values did not result in full phenotypic correction, and some muscle fibers showed little or no glycogen clearance. The results demonstrate that complete reversal of pathology in skeletal muscle or long-affected heart muscle will require much more enzyme than previously expected or a different approach.",
keywords = "Acid α-glocosidase, Knockout, Myopathy, Pompe disease, Transgenic",
author = "Nina Raben and Tejas Jatkar and Alicia Lee and Nina Lu and Sunita Dwivedi and Kanneboyina Nagaraju and Plotz, {Paul H.}",
year = "2002",
month = "11",
day = "1",
doi = "10.1016/S1525-0016(02)90716-1",
language = "English (US)",
volume = "6",
pages = "601--608",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Glycogen stored in skeletal but not in cardiac muscle in acid α-glucosidase mutant (Pompe) mice is highly resistant to transgene-encoded human enzyme

AU - Raben, Nina

AU - Jatkar, Tejas

AU - Lee, Alicia

AU - Lu, Nina

AU - Dwivedi, Sunita

AU - Nagaraju, Kanneboyina

AU - Plotz, Paul H.

PY - 2002/11/1

Y1 - 2002/11/1

N2 - Although many lysosomal disorders are corrected by a small amount of the missing enzyme, it has been generally accepted that 20-30% of normal acid α-glucosidase (GAA) activity, provided by gene or enzyme replacement therapy, would be required to reverse the myopathy and cardiomyopathy in Pompe disease. We have addressed the issue of reversibility of the disease in the Gaa-/- mouse model. We have made transgenic lines expressing human GAA in skeletal and cardiac muscle of Gaa-/- mice, and we turned the transgene on at different stages of disease progression by using a tetracycline-controllable system. We have demonstrated that levels of 20-30% of normal activity are indeed sufficient to clear glycogen in the heart of young Gaa-/- mice, but not in older mice with a considerably higher glycogen load. However, in skeletal muscle - a major organ affected in infantile and in milder, late-onset variants in humans - induction of GAA expression in young Gaa-/- mice to levels greatly exceeding wildtype values did not result in full phenotypic correction, and some muscle fibers showed little or no glycogen clearance. The results demonstrate that complete reversal of pathology in skeletal muscle or long-affected heart muscle will require much more enzyme than previously expected or a different approach.

AB - Although many lysosomal disorders are corrected by a small amount of the missing enzyme, it has been generally accepted that 20-30% of normal acid α-glucosidase (GAA) activity, provided by gene or enzyme replacement therapy, would be required to reverse the myopathy and cardiomyopathy in Pompe disease. We have addressed the issue of reversibility of the disease in the Gaa-/- mouse model. We have made transgenic lines expressing human GAA in skeletal and cardiac muscle of Gaa-/- mice, and we turned the transgene on at different stages of disease progression by using a tetracycline-controllable system. We have demonstrated that levels of 20-30% of normal activity are indeed sufficient to clear glycogen in the heart of young Gaa-/- mice, but not in older mice with a considerably higher glycogen load. However, in skeletal muscle - a major organ affected in infantile and in milder, late-onset variants in humans - induction of GAA expression in young Gaa-/- mice to levels greatly exceeding wildtype values did not result in full phenotypic correction, and some muscle fibers showed little or no glycogen clearance. The results demonstrate that complete reversal of pathology in skeletal muscle or long-affected heart muscle will require much more enzyme than previously expected or a different approach.

KW - Acid α-glocosidase

KW - Knockout

KW - Myopathy

KW - Pompe disease

KW - Transgenic

UR - http://www.scopus.com/inward/record.url?scp=0036853028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036853028&partnerID=8YFLogxK

U2 - 10.1016/S1525-0016(02)90716-1

DO - 10.1016/S1525-0016(02)90716-1

M3 - Article

VL - 6

SP - 601

EP - 608

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 5

ER -